Paucatalinone A from Paulownia Catalpifolia Gong Tong Elicits mitochondrial-mediated cancer cell death to combat osteosarcoma
This study underscores the potential of Paucatalinone A in initiating apoptosis in cancer cells and highlights the therapeutic efficacy of plant-derived agents in treating osteosarcoma, offering a viable approach for managing other intractable cancers. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 25, 2024 Category: Drugs & Pharmacology Source Type: research
Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing
AbstractOsteosarcoma (OS) stands as the most prevalent primary bone cancer in children and adolescents, and its limited treatment options often result in unsatisfactory outcomes, particularly for metastatic cases. The tumor microenvironment (TME) has been recognized as a crucial determinant in OS progression. However, the intercellular dynamics between high TP53-expressing OS cells and neighboring cell types within the TME are yet to be thoroughly understood. In our study, we harnessed the single-cell RNA sequencing (scRNA-seq) technology in combination with the computational tool –Cellchat, aiming to elucidate the inter...
Source: Medical Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma
Biochem Biophys Res Commun. 2024 Mar 20;708:149808. doi: 10.1016/j.bbrc.2024.149808. Online ahead of print.ABSTRACTOsteosarcoma is the most common malignant bone tumor. It has a poor prognosis because of a lack of therapeutic targets and strategies. The SET domain-containing lysine-specific methyltransferase, SET7/9, has various functions in different cancer types in tissue-type and signaling context-dependent manners. The role of SET7/9 in osteosarcoma cells is currently controversial and its potential as a therapeutic candidate in osteosarcoma is unknown. In the present study, SET7/9 inhibition or ablation suppressed ost...
Source: Biochemical and Biophysical Research communications - March 23, 2024 Category: Biochemistry Authors: Yingxu Shi Zhonghao Wang Yiming Shao Qianqian Guang Jian Zhang Baorui Liu Chunshen Wu Yexin Wang Ping Sui Source Type: research
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma
Biochem Biophys Res Commun. 2024 Mar 20;708:149808. doi: 10.1016/j.bbrc.2024.149808. Online ahead of print.ABSTRACTOsteosarcoma is the most common malignant bone tumor. It has a poor prognosis because of a lack of therapeutic targets and strategies. The SET domain-containing lysine-specific methyltransferase, SET7/9, has various functions in different cancer types in tissue-type and signaling context-dependent manners. The role of SET7/9 in osteosarcoma cells is currently controversial and its potential as a therapeutic candidate in osteosarcoma is unknown. In the present study, SET7/9 inhibition or ablation suppressed ost...
Source: Cell Research - March 23, 2024 Category: Cytology Authors: Yingxu Shi Zhonghao Wang Yiming Shao Qianqian Guang Jian Zhang Baorui Liu Chunshen Wu Yexin Wang Ping Sui Source Type: research
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)
CONCLUSIONS: Pepinemab (20 mg/kg) is safe, well tolerated and resulted in adequate and sustained target saturation in pediatric patients. Encouraging disease control in two patients with osteosarcoma warrants further investigation with novel combination strategies to modulate the tumor microenvironment and antitumor immune response.CLINICAL TRIAL REGISTRY: This trial is registered as NCT03320330 at Clinicaltrials.gov.DISCLAIMER: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.PMID:38520670 | DOI:10.1002/pbc.30938 (Source: Cancer Control)
Source: Cancer Control - March 23, 2024 Category: Cancer & Oncology Authors: Emily Greengard Robin Williams Branden Moriarity Xiaowei Liu Charles G Minard Joel M Reid Terrence Fisher Elizabeth Evans Desa Rae Pastore Maurice Zauderer Stephan Voss Elizabeth Fox Brenda J Weigel Source Type: research
Intraoperative radiation therapy for pediatric sarcomas and other solid tumors
CONCLUSION: Our study represents the largest and most recent analysis of efficacy and safety of IORT in pediatric patients with ST. Less than one quarter of all patients failed locally with acceptable toxicities. Overall, IORT is an effective and safe technique to achieve local control in patients with challenging circumstances.PMID:38520048 | DOI:10.1002/pbc.30949 (Source: Cancer Control)
Source: Cancer Control - March 23, 2024 Category: Cancer & Oncology Authors: Brianna Conte Dana L Casey Kathryn R Tringale Michael P LaQuaglia J Ted Gerstle Leonard Wexler Michael V Ortiz Suzanne L Wolden Source Type: research
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma
Biochem Biophys Res Commun. 2024 Mar 20;708:149808. doi: 10.1016/j.bbrc.2024.149808. Online ahead of print.ABSTRACTOsteosarcoma is the most common malignant bone tumor. It has a poor prognosis because of a lack of therapeutic targets and strategies. The SET domain-containing lysine-specific methyltransferase, SET7/9, has various functions in different cancer types in tissue-type and signaling context-dependent manners. The role of SET7/9 in osteosarcoma cells is currently controversial and its potential as a therapeutic candidate in osteosarcoma is unknown. In the present study, SET7/9 inhibition or ablation suppressed ost...
Source: Biochemical and Biophysical Research communications - March 23, 2024 Category: Biochemistry Authors: Yingxu Shi Zhonghao Wang Yiming Shao Qianqian Guang Jian Zhang Baorui Liu Chunshen Wu Yexin Wang Ping Sui Source Type: research
Identification of allograft inflammatory factor-1 suppressing the progression and indicating good prognosis of osteosarcoma
Osteosarcoma is one of the most common cancers worldwide. Intense efforts have been made to elucidate the pathogeny, but the mechanisms of osteosarcoma are still not well understood. We aimed to investigate th... (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - March 23, 2024 Category: Orthopaedics Authors: Wenda Liu, Tao Shi, Di Zheng, Guangshui Ke and Jingteng Chen Tags: Research Source Type: research
Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study
ConclusionImmunotherapy is an effective treatment modality for sarcoma with manageable safety. Further inclusion of more patients or prospective clinical trials is needed to validate these findings. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 22, 2024 Category: Allergy & Immunology Source Type: research
Intercalary Resection of the Tibia for Primary Bone Tumors: Are Vascularized Fibula Autografts With or Without Allografts a Durable Reconstruction?
CONCLUSION: VFG, alone or combined with an allograft, could be considered in reconstructing a lower extremity after intercalary resections of the tibia for primary bone tumors, and it avoids the use of a large endoprosthesis. However, this procedure was associated with frequent, often severe complications during the first postoperative years and complication-free survival of 58% at 5 years. Nearly 10% of patients ultimately had an amputation. For patients whose reconstruction succeeded, the technique provides a durable reconstruction with good MSTS scores, and we believe it is useful for active patients with long life expe...
Source: Cell Research - March 21, 2024 Category: Cytology Authors: Domenico Andrea Campanacci Roberto Scanferla Mariagrazia Marsico Federico Scolari Guido Scoccianti Giovanni Beltrami Luca Delcroix Marco Innocenti Rodolfo Capanna Source Type: research
